David Barbie, Chief of Thoracic Oncology at Dana-Farber Cancer Institute, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Proud of this review led by my talented graduate student Caroline Fahey and outstanding physician scientists Anthony Cordova and Patrick Gedeon. It took many years to translate adaptive immune therapies and RAS targeted therapies into the clinic.
Thus, the initial disappointing results from STING agonist trials need to be contextualized, since next generation approaches to target this pathway could still lead to eventual breakthroughs.”
Title: Targeting STING to generate therapeutic anti-tumor immunity
Authors: Caroline G. Fahey, Anthony F. Cordova, Patrick C. Gedeon, David A. Barbie
Read the Full Article on Cancer Cell
More posts featuring David Barbie